Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Attenuated Chédiak-Higashi syndrome (CHS) is a very rare and atypical form of CHS, a genetic disorder characterized by partial oculocutaneous albinism (OCA), severe immunodeficiency, mild bleeding, neurological dysfunction and lymphoproliferative disorder.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for attenuated Chédiak-Higashi syndrome.
2 publications have been identified in PubMed for attenuated Chédiak-Higashi syndrome. Research spans Case Report / Case Series (100%).
Amri Y (2025). [PMID: 40426172](https://pubmed.ncbi.nlm.nih.gov/40426172/). *BMC Med Genomics*. [Case Report / Case Series]
Kundavaram R (2024). [PMID: 39881889](https://pubmed.ncbi.nlm.nih.gov/39881889/). *Cureus*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:50 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center